Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

J&J's Actelion Courtship Seen Unaffected By Macitentan MAESTRO Failure

Executive Summary

Johnson & Johnson is expected to keep pursuing Actelion despite news the target's pulmonary arterial hypertension drug macitentan missed a primary endpoint in a Phase III study of patients with PAH due to Eisenmenger Syndrome.

Advertisement

Related Content

Can Actelion Founder Clozel Recreate Another Top Biotech Post-J&J Sale?
Fresh From The White House, J&J's Gorsky Talks Policy, Drug Pricing
Deal Watch: More Predictions 2017 Will Be A Banner Year For Deal-Making
Will Sanofi Overpay For Actelion Innovation Or, Like J&J, Also Walk Away?
Actelion's Opsumit Shows MERIT In CTEPH

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register